Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD

Add to favourite

0.3090

21.99%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.0059

Long position overnight fee

-0.023401%

Short position overnight fee

0.001179%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.2533
Open	0.294
1-Year Change	-72.26%
Day's Range	0.2635 - 0.312

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Jul 18, 2023	0.3090	0.0041	1.34%	0.3049	0.3209	0.2601
Jul 17, 2023	0.2533	-0.0607	-19.33%	0.3140	0.3166	0.2491
Jul 14, 2023	0.3153	-0.0302	-8.74%	0.3455	0.3455	0.3090
Jul 13, 2023	0.3490	0.0454	14.95%	0.3036	0.3588	0.2790
Jul 12, 2023	0.3289	-0.0499	-13.17%	0.3788	0.3987	0.3153
Jul 11, 2023	0.2606	0.0114	4.57%	0.2492	0.2669	0.2490
Jul 10, 2023	0.2617	0.0227	9.50%	0.2390	0.2638	0.2390
Jul 7, 2023	0.2491	0.0257	11.50%	0.2234	0.2502	0.2234
Jul 6, 2023	0.2263	0.0046	2.07%	0.2217	0.2321	0.2213
Jul 5, 2023	0.2272	0.0080	3.65%	0.2192	0.2332	0.2192
Jul 3, 2023	0.2148	0.0006	0.28%	0.2142	0.2259	0.2142
Jun 30, 2023	0.2144	-0.0025	-1.15%	0.2169	0.2169	0.1993
Jun 29, 2023	0.2129	0.0037	1.77%	0.2092	0.2167	0.2092
Jun 28, 2023	0.2116	-0.0276	-11.54%	0.2392	0.2392	0.2092
Jun 27, 2023	0.2413	-0.0088	-3.52%	0.2501	0.2531	0.2345
Jun 26, 2023	0.2492	-0.0099	-3.82%	0.2591	0.2591	0.2491
Jun 23, 2023	0.2597	0.0051	2.00%	0.2546	0.2603	0.2492
Jun 22, 2023	0.2566	-0.0025	-0.96%	0.2591	0.2591	0.2541
Jun 21, 2023	0.2565	0.0043	1.70%	0.2522	0.2601	0.2501
Jun 20, 2023	0.2552	-0.0014	-0.55%	0.2566	0.2671	0.2516

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aridis Pharmaceuticals, Inc. Company profile

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).

Industry:

Bio Therapeutic Drugs

983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US

News

Pi Network coin price prediction: Third party price target

Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com

13:51, 13 December 2024

Euro forecast: third party data roundup

In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.

22:39, 12 December 2024

Projected US interest rates in 5 years: Third party round up

As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?

14:28, 12 December 2024

Street in City of London with Royal Exchange, Bank of England and new modern skyscrapers

Projected UK interest rates in 5 years

Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?

11:20, 12 December 2024